About Orbis Biosciences
Orbis Biosciences is a company based in United States founded in 2008 was acquired by Adare Pharma Solutions in April 2020. Orbis Biosciences has raised $677.06 thousand across 11 funding rounds from investors including HHS and Adare Pharma Solutions. Orbis Biosciences operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Kansas, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$677.06 K (USD)
in 11 rounds
-
Latest Funding Round
$224.96 K (USD), Grant
Jul 07, 2017
-
Investors
HHS
& 1 more
-
Employee Count
Not available
-
Acquired by
Adare Pharma Solutions
(Apr 30, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Orbis Biosciences
Orbis Biosciences has successfully raised a total of $677.06K across 11 strategic funding rounds. The most recent funding activity was a Grant round of $224.96 thousand completed in July 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Orbis Biosciences
Orbis Biosciences has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Adare Pharma Solutions.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
CDMO manufacturing solid drugs
|
Locked | Locked | Locked |
Investor details for Orbis Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Orbis Biosciences
Investment portfolio details for Orbis Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Orbis Biosciences
Detailed financials for Orbis Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Orbis Biosciences Comparisons
Peer comparison for Orbis Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Orbis Biosciences
Orbis Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Orbis Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Orbis Biosciences
Complete news archive for Orbis Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Orbis Biosciences
Orbis Biosciences was founded in 2008.
Orbis Biosciences is headquartered in United States. It is registered at Kansas, United States.
Orbis Biosciences is a funded company, having raised a total of $677.06K across 11 funding rounds to date.
Orbis Biosciences was founded in 2008 in Kansas, United States, and focuses on controlled-release delivery systems for the pharmaceutical, consumer product, chemical, and food and beverage sectors. Precision Particle Fabrication technology is utilized to enable product creation involving small molecules, macromolecules, polymers, nucleic acids, proteins, chemotherapeutics, and biologics. A lead candidate, a controlled-release form of prednisone, is currently in phase I clinical trials.
Orbis Biosciences's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Orbis Biosciences has 2 investors. Key investors include HHS, and Adare Pharma Solutions.